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Cell surface biomarkers have been applied to discriminate pluripotent human embryonic stem cells and
induced pluripotent stem cells from differentiated cells. Here, we demonstrate that a recombinant lectin
probe, rBC2LCN, a new tool for ﬂuorescence-based imaging and ﬂow cytometry analysis of pluripotent
stem cells, is an alternative to conventional pluripotent maker antibodies. Live or ﬁxed colonies of both
human embryonic stem cells and induced pluripotent stem cells were visualized in culture medium con-
taining ﬂuorescent dye-labeled rBC2LCN. Fluorescent dye-labeled rBC2LCN was also successfully used to
separate live pluripotent stem cells from a mixed cell population by ﬂow cytometry.
 2013 Elsevier Inc. Open access under CC BY-NC-ND license. 1. Introduction
Both positive and negative selection of pluripotent stem cells
are key steps for practical applications, such as reducing risk of ter-
atoma formation in transplantation therapy, and maintaining a
homogeneous pluripotent cell population in continuous culture.
Recent studies have focused on cell surface markers, which are
speciﬁcally expressed on human embryonic stem cells (hESCs)
and human induced pluripotent stem cells (hiPSCs), for visualizing
and sorting stem cells by ﬂow cytometry or magnetic cell separa-
tion. The conventionally used markers are cell surface glycans spe-
ciﬁc for pluripotent stem cells, and antibodies for those glycans are
well established, such as stage-speciﬁc embryonic antigens-3, -4,
and-5 (SSEA-3, SSEA-4, SSEA-5), and tumor rejection antigens-1–
60 and -1–81 (TRA-1–60, TRA-1–81) [1–5]. Several lectin proteins,
which bind to unique glycans, are also useful probes for identifying
pluripotent stem cells. UEA-I, which is a lectin isolated through ar-
ray-based glycomic analysis, has high efﬁciency to detect human
pluripotent stem cells [6]. We also have identiﬁed that rBC2LCN,
which is a recombinant peptide corresponding to the N-terminal
domain of BC2L-C protein, speciﬁcally detects undifferentiated iPS-
Cs and ESCs in a lectin microarray system [7,8]. rBC2LCN binds spe-
ciﬁcally to Fuca1–2Galb1–3GlcNAc (GalNAc)-containing glycans,
such as H type1 (Fuca1–2Galb1–3GlcNAc), H type3 (Fuca1–
2Galb1–3GalNAc), Lewis b (Fuca1–2Galb1–3(Fuca1–4)GlcNAc)
and Globo H (Fuca1–2Galb1–3GalNAcb1–3Gala1–4Galb1–4Glc)
(Supplementary Fig. S1) [7,8]. Globo H is expressed on the surfaceC-ND license. of undifferentiated hESCs [5], and anti-SSEA-5 antibody is reported
to bind to H type1 antigen [4]. In addition, we have demonstrated
the presence of a-1–2 linked fucose in both N- and O-linked gly-
cans of iPSCs [9].
In this study, we demonstrate the potential of rBC2LCN as a
probe for pluripotent ESCs and iPSCs in both imaging and ﬂow
cytometry. Fluorescent dye-labeled rBC2LCN stained human ESCs
and hiPSCs and exhibited higher sensitivity upon iPSC differentia-
tion, compared to the established cell surface marker antibodies.
Fluorescent dye-labeled rBC2LCN was also capable of visualizing
and separating live pluripotent hESCs and hiPSCs by ﬂow cytome-
try. rBC2LCN is a useful tool for evaluating human ESCs and hiPSCs
and holds promise for improving cell sorting efﬁciency in medical
and industrial applications of pluripotent stem cells.
2. Materials and methods
2.1. Cell culture
KhES-1 and KhES-3 cells were maintained as previously de-
scribed [10]. Human ES cell line, H1, was maintained according
to WiCell Feeder Independent Pluripotent Stem Cell Protocols pro-
vided by the WiCell Research Institute (http://www.wicell.org).
Human iPS cell lines, 201B7 [11] and 253G1 [12], were maintained
in DMEM-F12 medium (Invitrogen) supplemented with 20% of KSR
(Invitrogen), 0.1 mM of 2-mercaptoethanol (Sigma–Aldrich), MEM
non-essential amino acids (Invitrogen), and 10 ng/ml of recombi-
nant human basic FGF (Wako) on mitomycin C-treated mouse em-
bryo ﬁbroblast feeder cells. The 201B7 cell line was cultured in
mTeSR1 (STEMCELL Technologies) on BD Matrigel hESC-qualiﬁed
Fig. 1. Fluorescent dye-labeled rBC2LCN directly stains hiPSC colonies. (A–D) A 253G1 iPSC colony stained with FITC-conjugated rBC2LCN (A), anti-Nanog antibody (B) and
DAPI (C), and the overlay of A–C images (D). (E) Confocal image of 201B7 cells stained with Cy3-conjugated rBC2LCN and DAPI. rBC2LCN signal can be observed on the cell
membrane. (F–J, F0–J0) Chronological live cell imaging of 201B7 iPSC using Cy3-conjugated rBC2LCN in 0.1 lg/mL of ﬁnal concentration. (K-Q) H1 ESCs were treated with
100 lg/mL rBC2LCN or 1 lg/mL of FITC-rBC2LCN for 3 days. (K–M) Cell morphologies of H1 ESCs without treatment (K), 100 lg/mL of rBC2LCN treatment (L), and 1 lg/mL of
FITC-rBC2LCN treatment (M and M0). Treatment with rBC2LCN caused no signiﬁcant morphological changes. (N–Q) Scatter plot showing log2 transformed average expression
values from gene expression proﬁles between untreated H1 cells and H1 cells treated with 100 lg/mL of rBC2LCN (N) or 1 lg/mL of FITC-rBC2LCN (O), KhES-1 ESCs (P), or HDF
(Q), using arrayed 60 k probe sets. Pearson correlation coefﬁcients (r), using all probes, between untreated and treated cells are indicated. One typical data set of two
independent, duplicate examinations is shown. The full array data set was deposited in the GEO databank (GSE42976). Black lines indicate 2-fold up-regulation and down-
regulation. Scale bar: 10 lm in (E). 100 lm in others.
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man adult dermal ﬁbroblast (HDF) cells were cultured in ﬁbroblast
basal medium (ATCC) supplemented with ﬁbroblast growth kit-
low serum (ATCC).
2.2. Lectin labeling and staining
rBC2LCN protein was prepared according to a previous paper
[8]. For ﬂuorescence labeling, rBC2LCN was labeled withCy3-N-
hydroxysuccinimide (NHS) ester (GE Healthcare), ﬂuorescein-4-
isothiocyanate (FITC, Dojindo), and HiLyte Fluor 647 Labeling
Kit (Dojindo), respectively. Fixed cell staining was performed as
described previously [13]. Brieﬂy, hESCs and hiPSCs were ﬁxed
with 4% paraformaldehyde for 10–60 min at 4 C or room tem-
perature. After rinsing with PBS, cells were incubated with
10 lg/mL of Cy3- or FITC-conjugated rBC2LCN diluted in 1%
BSA containing PBS for 1 h at room temperature. The cells were
counterstained with DAPI (Dojindo), and then images were col-
lected with a BIOREVO BZ-9000 ﬂuorescence microscope (Key-
ence) and a FluoView FV1000 confocal laser scanning
microscope (Olympus).
Live cell imaging was performed in the regular hESC or iPSC cul-
ture medium (with phenol red) by addition of Cy3- or FITC-conju-gated rBC2LCN in 0.1–1 lg/mL of ﬁnal concentration. After 2 h
incubation under typical culture conditions, images were collected
with an Axiovert 40 CFL inverted microscope (Carl Zeiss Micros-
copy), without washing. For chronological observations, the same
concentration of ﬂuorescent dye-labeled rBC2LCN was added with
daily medium changes.2.3. Immunocytochemistry
Immunocytochemical analysis was performed as described pre-
viously [14–16]. Primary antibodies used in this study were the
following: anti-SSEA4 (MC-813–70, 1:300 dilution; Millipore),
anti-TRA-1–60 (1:300 dilution; Millipore), anti-TRA-1–81 (1:300
dilution; Millipore), anti-Oct-3/4 (1:300 dilution; Santa Cruz Bio-
technology), and anti-human-Nanog (1:800 dilution; Cell Signaling
Technology). Cells were incubated with a primary antibody diluted
in 1% BSA and 5% serum containing PBS at 4 C overnight. Second-
ary staining was performed with an appropriate secondary anti-
body conjugated to Alexa Fluor 488 or Alexa Fluor 594 (1:300;
Invitrogen) for 1 h at room temperature. Cells were counterstained
with DAPI (Dojindo). Images were collected with a BIOREVO BZ-
9000 ﬂuorescence microscope (Keyence).
Fig. 2. rBC2LCN is a speciﬁc probe for hESCs and hiPSCs in FACS. (A–C) Histogram of representative FACS plots. Non-pluripotent HDF cells (A), KhES-1 hESCs (B), and 253G1
hiPSCs (C) were incubated with HiLyte Fluor 647-conjugated rBC2LCN (solid line) or buffer (dash line). rBC2LCN-binding shifts were observed in both hESCs (B) and hiPSCs
(C), but not in HDF cells (A). (D–K) Multi-color ﬂow cytometric analysis of KhES-1 (D, E, H, and I) and 253G1 (F, G, J, and K) with HiLyte Fluor 647-conjugated rBC2LCN and
with pluripotent marker antibodies, anti-SSEA-4 (D-G) or anti-TRA-1–60 (H–K). (D, F, H, and J) Cells were ﬁrst treated with HiLyte Fluor 647-labelled rBC2LCN, and then
treated with either anti-SSEA-4 or anti-TRA-1–60 antibody; subsequently, cells were treated with an appropriate secondary antibody. (E, G, I, K) Cells were ﬁrst treated with
either anti-SSEA-4 or anti-TRA-1–60 antibody, and were then further treated with an appropriate secondary antibody. Next, cells were treated with HiLyte Fluor 647-labelled
rBC2LCN. Multi-color FACS plots display substantial overlaps of cell populations bound to rBC2LCN, and anti-SSEA-4 and anti-TRA-1–60 antibodies. Values in each quadrant
indicate the percentage of cells.
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HDF cells were pre-marked with a CellTrace Violet Cell Prolif-
eration Kit according to the manufacturer’s protocol (Invitrogen).
KhES-1 and 253G1 colonies were treated in a solution that con-
tained 1 mg/mL collagenase IV (Invitrogen), 1 mM CaCl2, 20%
KNOCKOUT Serum Replacement (Invitrogen), and 0.25% trypsin
(Invitrogen), in a 37 C incubator. When the edges of the colonies
began to dissociate from the bottom of the dish, the solution was
removed and the cells rinsed with medium. Colonies were col-
lected and rinsed with PBS to remove feeder cells, and were then
dissociated with accutase (Millipore). The dissociated ESCs or iPS-
Cs were resuspended at approximately 1  106 cells/mL in MACS
buffer (0.5% bovine serum albumin and 2 mM EDTA in PBS),
and incubated with primary antibodies or 1 lg/mL of HiLyte Fluor
647-conjugated rBC2LCN for 1 h at 4 C. Primary antibodies used
were the following: anti-SSEA4 (1:300 dilution; Millipore) and
anti-TRA-1–60 (1:300 dilution; Millipore). For secondary antibody
treatment, cells were rinsed with MACS buffer and then incu-
bated with Alexa Fluor 488 goat anti-mouse IgM or Alexa Fluor
488 anti-mouse IgG (Molecular Probes), depending on the pri-
mary antibody. After further rinsing, cells were stained with pro-
pidium iodide (PI) and 20,000 cells were counted using a FACS
Aria (BD Biosciences). The data were analyzed with FlowJo soft-
ware (Tree Star, Inc.).2.5. Differentiation assays
Retinoic acid treatment was carried out as previously described
[17,18]. 253G1 cells were treated with the regular maintenance
medium, including all-trans retinoic acid at a ﬁnal concentration
of 105 M for 8 days. Both retinoic acid-treated and untreated cells
were ﬁxed at day 5 and 8, respectively, and prepared for lectin
staining and immunocytochemistry.
2.6. DNA microarray and analyses
Total RNA was extracted from frozen cell samples using ISOGEN
(NIPPON GENE) according to the manufacturer’s instructions. Sam-
ples were analyzed using an Agilent SurePrint G3 Human GE
8  60 K Microarray Kit (G4851A) and a Low Input Quick Amp
Labeling Kit, 1 color (Agilent). Arrays were scanned using a
G2505CMicroarray Scanner System (Agilent). Rawmicroarray data
were submitted to the Gene Expression Omnibus (GEO) microarray
data archive (http://www.ncbi.nlm.nih.gov/geo/) at NCBI (acces-
sion number GSE42976).
Data were analyzed using Gene-Spring GX12.0 software (Agi-
lent) after applying two normalization procedures: (1) signal
intensities of <1 were set to 1, and (2) each chip was normalized
to the 75th percentile of all measurements from that chip. Baseline
transformation of these data was not performed.
Fig. 3. rBC2LCN staining on differentiating iPS cells. 253G1 iPSCs were treated with retinoic acid for 5 days. (A–F) Control pluripotent iPSC colonies. Signals of rBC2LCN and
pluripotent marker antibodies were observed. (G–L) Retinoic acid-treated cells. rBC2LCN signal was signiﬁcantly reduced by 5 days’ treatment (G), compared to treatment
with established pluripotent marker antibodies, anti-Nanog (H), anti-Oct4 (I), anti-SSEA-4 (J), anti-TRA-1–60 (K), and anti-TRA-1–81(L). Scale bar: 100 lm.
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3.1. rBC2LCN is a speciﬁc probe for human pluripotent stem cells
To discover new markers for hESCs and hiPSCs, we performed
comprehensive glycan analysis using a high-density lectin micro-
array and selected a candidate lectin, rBC2LCN [8]. To establish
whether rBC2LCN could be used as a probe for pluripotent stem
cells, we ﬁrst performed lectin-staining using ﬂuorescent dye-la-
beled rBC2LCN (Fig. 1). Strong ﬂuorescence signals were observed
for hiPSC colonies (253G1), but no signal was detectable for mouse
embryonic ﬁbroblasts (MEF), which were co-cultured as feeder
cells (Fig. 1A–D). rBC2LCN staining was observed on the cell mem-
brane of hiPSCs by confocal microscopic observation (Fig. 1E). This
was in good agreement with previous reports that rBC2LCN-bind-
ing glycans are present on the surface of undifferentiated stem
cells [8]. We also examined whether ﬂuorescent dye-labeled
rBC2LCN stains live pluripotent stem cell. Chronological observa-
tion of 201B7 iPSC cultured in the regular maintenance medium
with Cy3-conjugated rBC2LCN, at a ﬁnal concentration of 0.1 lg/
mL, yielded clear live cell images under a conventional ﬂorescent
microscope (Fig. 1F–J). A similar staining pattern was observed in
3 different hESC lines (KhES-1, KhES-3, and H1; Fig. 1M, Supple-
mentary Fig. S2). These results indicated that ﬂuorescent dye-la-
beled rBC2LCN stains both ﬁxed and live hESC/hiPSCs on the cell
membrane.
We observed no signiﬁcant changes in colony growth during
chronological live cell imaging (Fig. 1F–J). Furthermore, we evalu-
ated the inﬂuence of rBC2LCN treatment on pluripotent stem cells.
H1 ESCs were cultured in regular maintenance medium with
100 lg/mL of rBC2LCN or 1 lg/mL of FITC-conjugated rBC2LCN
for 3 days. The sizes and morphologies of the colonies of the un-
treated and rBC2LCN or FITC-conjugated rBC2LCN treated cells
were not signiﬁcantly different (Fig. 1K–M).
We further analyzed global gene expression under each condi-
tion by DNA microarray (Fig. 1N–Q). The correlation coefﬁcientsof gene expression using all probes (about 60 K) between un-
treated cells and cells treated with 100 lg/mL of rBC2LCN or
1 lg/mL of FITC-conjugated rBC2LCN,were high (0.998 and 0.996,
respectively; Fig. 1N–O). Scatter plots also showed very similar
gene expression proﬁles between untreated cells and cells treated
with rBC2LCN or FITC-conjugated rBC2LCN. The differences were
much smaller than that between H1 ESCs and KhES-1 hESCs
(r = 0.984; Fig. 1P). These results indicated that hESCs cultured in
the presence of rBC2LCN largely maintained normal gene expres-
sion proﬁle.
Further analysis of the speciﬁcity of rBC2LCN for undifferenti-
ated pluripotent stem cells was carried out by ﬂow cytometry
(Fig. 2). rBC2LCN bound selectively to hESCs and hiPSCs, and did
not bind to human dermal ﬁbroblast (HDF) cells (Fig. 2A–C). This
result indicated that pluripotent cells present glycan markers rec-
ognized by rBC2LCN. In multi-color ﬂow cytometric analysis,
rBC2LCN-binding cells were also positive for pluripotency markers,
TRA-1–60 and SSEA-4 (Fig. 2D–K). When cells were treated with
these antibodies either before or after treatment with rBC2LCN,
the treatment order did not affect association of either antibody
and rBC2LCN (Fig. 2D and E). Most (99.1%) KhES-1 cells were dou-
ble-positivefor SSEA-4 and rBC2LCN when rBC2LCN treatment oc-
curred ﬁrst, and 99.4% of cells were double-positive when rBC2LCN
followed after antibody labeling (Fig. 2D and E). Anti-TRA-1–60
antibody also bound toKhES-1 cells that were positive for
rBC2LCN; 98.2% of cells were double-positive when rBC2LCN-treat-
ment occurred ﬁrst, and 98.0% when rBC2LCN-treatment occurred
last (Fig. 2H and I). Similar results were obtained with the hiPSC
line, 253G1 (Fig. 2F, G, J, and K). These results indicated that the
sensitivity and speciﬁcity of rBC2LCN was comparable to those of
established pluripotent marker antibodies.3.2. rBC2LCN is highly sensitive to cell differentiation
To examine rBC2LCN binding to a range of differentiated cells,
we performed rBC2LCN staining on cells differentiated by treat-
Fig. 4. rBC2LCN facilitates separation of hiPSCs from mixed cell population. Multi-color ﬂow cytometric analysis of 253G1 and HDF. (A) Non-pluripotent HDF cells, which
were ﬂuorescently labeled with CellTrace Violet, were incubated with HiLyte Fluor 647-labelled rBC2LCN. (B) 253G1 iPSCs were incubated with HiLyte Fluor 647-labelled
rBC2LCN. (C) CellTrace Violet-labeled HDF and 253G1 cells were mixed in a ratio of 1:1, and then the mixed cells were incubated with HiLyte Fluor 647-conjugated rBC2LCN.
(D) 253G1 cells were ﬁrst reacted with HiLyte Fluor 647-conjugated rBC2LCN. 253G1 cells were mixed with CellTrace Violet-labeled HDF cells in a ratio of 1:1, and prepared
for Multi-color FACS. Values in each quadrant indicate the percentage of cells. The rates of each quadrant population were similar between (C) and (D).
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were signiﬁcantly reduced after 5 days of treatment with retinoic
acid (Fig. 3G), compared with that of untreated hiPSCs (Fig. 3A).
We found that Nanog, Oct4, and SSEA-4 expression was also de-
creased, particularly in the center of colonies, whereas TRA-1–60
and TRA-1–81 signals remained high throughout colonies after
5 days of treatment with retinoic acid (Fig. 3H–L). TRA-1–60 and
TRA-1–81 signals were weak in 253G1 coloniesafter 8 days of
treatment with retinoic acid (Supplementary Fig. S3). The simulta-
neous reduction of rBC2LCN and Nanog expression during differen-
tiation, exhibits the utility of rBC2LCN for monitoring the
properties of pluripotent stem cells in culture.
Next, we attempted to use rBC2LCN for separation of hiPSCs
from a mixed cell population, also containing non-pluripotent
cells, by ﬂow cytometry (Fig. 4). HDFcells were pre-labeled with
CellTrace Violet and were mixed with 253G1 cells at a ratio of
1:1. The mixed cell population was incubated with HiLyte Fluor
647-conjugated rBC2LCN and was analyzed by multi-color FACS
(Fig. 4C). rBC2LCN+/CellTrace Violet-cells accounted for 50.4%,
and rBC2LCN/CellTrace Violet+-cells for 47.6%of the total number
of cells (Fig. 4C). rBC2LCN+/CellTrace Violet+-cells accounted only
for 0.057%of the total cell number. Thus the ratio was approxi-
mately 1:1, which corresponded to the proportion of pre-labeled
HDF and rBC2LCN-prebound 253G1 in the initial 1:1 mixed cell
population (Fig. 4D). These results suggest that rBC2LCN is a useful
probe for sorting live pluripotent stem cells from heterogeneous
cell cultures.
We identiﬁed rBC2LCN as a pluripotency-speciﬁc lectin probe,
which binds to the cell surface of undifferentiated human ESCs
and iPSCs. The binding capacity for both ﬁxed and live cells favored
the applicationof rBC2LCN in ﬂuorescence-based imaging and ﬂow
cytometry. In addition, rBC2LCN has a higher sensitivity for differ-
entiated cells than do the established cell surface marker antibod-
ies. Further studies will be required to address whether rBC2LCNis
effective for cell sorting to eliminate teratoma formation after
transplantation of hES or hiPS cell-derived differentiated cells.
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